Brief: Neoimmunetech Inc Says First Patient Dosed In Study Evaluating Nt-I7 & Keytruda In Advanced Solid Tumors
23/03/2021 11:07
March 23 (Reuters) - Neoimmunetech Inc (Pre-reincorporation)
950220.KQ :
* NEOIMMUNETECH INC - FIRST PATIENT DOSED IN PHASE 2A
PORTION OF
BASKET STUDY EVALUATING NT-I7 & KEYTRUDA IN RELAPSED/REFRACTORY
ADVANCED SOLID TUMORS
Source text for Eikon: ID:nBw9J4bP2a
Further company coverage: 950220.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neoimmunetech
See all newsBrief: Emmaus Life Sciences Enters License And Distribution Agreement With Neoimmunetech
Brief: Neoimmunetech To Conduct Capital Increase Of 65 Billion Won For Operational Funds
Brief: FDA Grants Orphan Drug Designation Status To NeoImmuneTech's NT-I7 For Advanced Pancreatic Cancer Treatment
Brief: FDA Grants Orphan Drug Tag to NeoImmuneTech's Acute Radiation Syndrome Treatment
Brief: Neoimmunetech Presents Phase 1 Study Data At Society For Neuro-Oncology Annual Meeting